Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factors influencing ribavirin-induced hemolysis.

Journal of hepatology - 1 Jun 2001

Van Vlierbergh H, Delanghe J R, De Vos M, Leroux-Roel G

Abstract excerpt

BACKGROUND/AIMS: One of the major side effects of the combination therapy for chronic hepatitis C is ribavirin-induced hemolytic anemia. Little is known about variables influencing this anemia. Our study tried to search for these variables in a large group of patients with hepatitis C treated with the combination therapy. METHODS: Two hundred and forty-four patients chronically infected with the hepatitis C virus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Hemolytic
Share to Haptoglobins
Share to Hemoglobins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemolysis

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Platelet Count

Share to Ribavirin

Source

Identifiers

PMID: 11451176
DOI: 10.1016/s0168-8278(01)00029-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factors influencing ribavirin-induced hemolysis.PMID 11451176Read ↗

Pharmacogenetics of ribavirin-induced anemia in HCV patients.Semantic proximity Read ↗

Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.Semantic proximity Read ↗

ITPA gene variation and ribavirin‐induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirinSemantic proximity Read ↗

Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.Semantic proximity Read ↗

Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.Semantic proximity Read ↗

Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.Semantic proximity Read ↗

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.Semantic proximity Read ↗

Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy.Semantic proximity Read ↗

Ribavirin: current role in the optimal clinical management of chronic hepatitis C.Semantic proximity Read ↗

Peg-interfon alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle-cell anemia in Saudi Arabia.Semantic proximity Read ↗

Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.Semantic proximity Read ↗

ITPA gene variant may protect against anemia induced during pegylated interferon alfa and ribavirin combination treatment in Ukrainian patients with chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.